Skip to main content
Prospective Students
Current Students
Residents & Fellows
Give to SMHS
Quick Links
Quick Links
Administrative Offices
Continuing Education in the Health Professions
Departments & Programs
GW Resiliency and Well-Being Center
GWish
GW Faculty Directory
Himmelfarb Library
The GW Vaccine Research Unit
Toggle navigation
Main navigation
About
Core Members
GW Clinical Immunology Lab
GW Medical Faculty Associates
Student Researchers
Research
Clinical Trial Capabilities
Clinical Trials
Partnerships
Volunteer
Publications
News
Latest News
News Archive
Videos
Moderna vaccine clinical trial at GW
Moderna COVID-19 Vaccine Trial - Q&A with Dr. David Diemert
Moderna COVID-19 Vaccine Trial - Q&A with Dr. Manya Magnus
Contact
Search
Search
Home
Respiratory viruses
Respiratory viruses
KEYWORD SEARCH
Apply
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
October 24, 2024
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
Pfizer's RSV vaccine, Abrysvo, has shown a strong immune response and well-tolerated safety profile in new study.
August 14, 2024
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
Subscribe to Respiratory viruses
